Inhibrx
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11025 N Torrey Pines Rd Ste 140, La Joll...Phone Number
(858) 795-4220Website
www.inhibrx.comRevenue
<$5 MillionStock Symbol
INBXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Inhibrx
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Explore more
Inhibrx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inhibrx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Inhibrx launches new products
Funding: Get notified immidiatlly once Inhibrx has new funding data
Website visits: Recent activity has been detected on your website
Inhibrx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Inhibrx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Inhibrx recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Inhibrx
Check out if Inhibrx is spiking on competitors!
Click to see if Inhibrx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Inhibrx
Compare insights from companies similar to Inhibrx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Public
$29.8M
1997
LW
Lauren WittberAssociate Director, Accounting, SEC Reporting & Financial Analysis
Company Profile Activity
Activity Insights
Inhibrx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inhibrx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inhibrx.
Inhibrx financials insights
Gather financial insights about Inhibrx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$20M
2020
Debt
$1M
Inhibrx Tech Stack
A closer look at the technologies used by Inhibrx
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Inhibrx has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Order Entry.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Inhibrx News & Media
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone Results are most pronounced in HPV+ patients, with...Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic...Inhibrx Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and...Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 ... - TradingView
Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500.0 million via a second amendment, receiving $100.0 million at closing (Term C) and access to up to $225.0 million more at the lenders’ discretion in $50.0 million or larger increments…
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Inhibrx
Sign Up For FreeTo access detailed company insights
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or m... Read More
